

Edinburgh Scotland IUPHAR Mentoring Center

Site

Pharmacology, Toxicology and Therapeutics, University of Edinburgh

Address

Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, Scotland, UK

Contact

Email to Prof David Webb (d.j.webb@ed.ac.uk)

Affiliations

- British Heart Foundation Edinburgh Centre of Research Excellence (CoRE)
- Clinical Pharmacology Unit (CPU) and Research Centre (CRC)
- Scottish Poisons Information Bureau (SPIB), Edinburgh Royal Infirmary

Key individuals (and expertise)

- Dr James Dear, Clinical toxicology, biomarkers (renal/liver) and miRNA
- Dr Bean (Neeraj) Dhaun, Renal, translational research and clinical trials
- Prof Michael Eddleston, Clinical toxicology, FIH, clinical trials in resource-poor countries
- Prof Simon Maxwell, Education, HTA, prescribing safety/skills assessment (PSA)
- Prof David Newby, Cardiology, FIH, translational research and clinical trials
- Prof David Webb, Hypertension, FIH, HTA, translational research & clinical trials

[FIH = 'First in human' studies]

Research expertise

- Biomarkers
- Clinical toxicology
- Clinical trials
- Education
- First-in-human studies
- Formulary development and management
- Health technology assessment
- Hypertension
- Prescribing skills and their assessment
- Acute kidney injury, chronic and end-stage kidney disease
- Translational research
- Clinical research techniques – protocol design; measurement of arterial stiffness, blood pressure, endothelial function, forearm blood flow/plethysmography and renal function

Opportunities on offer

- Email/Skype advice on clinical research study design
- Email/Skype advice on research in our areas of expertise

- Email/Skype advice on educational/curricular plans
- Email/Skype advice on safe prescribing
- Potential relevant collaborations in areas of mutual interest
- Willingness to host self-funded visitors/fellowships in areas of mutual interest

Selected Publications

1. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. *Lancet* 1994;344:852-4.
2. Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, Webb DJ. Endothelin- A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. *Circulation* 2004;109:1186-93.
3. Eddleston M, Eyer P, Worek F, Juzszak E, Alder N, Mohamed F, Senarathna L, Hittarage A, Azher S, Jeganathan K, Jayamanne S, von Meyer L, Dawson AH, Sheriff MHR, Buckley NA. Pralidoxime in acute organophosphorus insecticide poisoning: a randomised controlled trial. *PLoS Med* 2009;6:e1000104
4. Dhaun N, Macintyre IM, Kerr D, Melville V, Johnston NR, Haughie S, Goddard J, Webb DJ. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. *Hypertension* 2011;57:772-9.
5. Starkey-Lewis PJ, Dear J, Platt V, Simpson KJ., Craig DGN, Antoine DJ, French NS, Dhaun N, Webb DJ, Costello EM, Neoptolemos JP, Mogg J, Goldring CE, Park K. Circulating microRNAs as potential markers of human drug induced liver injury. *Hepatology* 2011;54:1767-76.
6. Ross S, Maxwell S. Prescribing and the core curriculum for tomorrow's doctors: BPS Curriculum in Clinical Pharmacology and Prescribing for Medical Students. *British Journal of Clinical Pharmacology* 2012;74:644–661.
7. Antoine DJ, Dear JW, Starkey-Lewis PJ, Platt V, Coyle J, Masson M, Thanacoody RH, Gray AJ, Webb DJ, Moggs JG, Bateman DN, Goldring CE, Park K. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. *Hepatology* 2013;58:777-787.
8. Dhaun N, Moorhouse R, MacIntyre IM, Melville V, Oosthuyzen W, Kimmitt RA, Brown KE, Kennedy ED, Goddard J, Webb DJ. Diurnal variation in blood pressure and arterial stiffness in chronic kidney disease: the role of endothelin-1. *Hypertension* 2014;64:296-304.
9. Ryan C, Ross S, Davey P, et al. Prevalence and causes of prescribing errors: the PRescribing Outcomes for Trainee Doctors Engaged in Clinical Training (PROTECT) study. *PLoS One* 2014;9:e79802.
10. Hulse EJ, Davies JOJ, Simpson AJ, Sciuto A, Eddleston M. Respiratory complications of organophosphorus nerve agent and insecticide poisoning - implications for respiratory and critical care. *Am J Resp Crit Care Med* 2014;190:1342-1354.
11. Bateman DN, Dear JW, Thanacoody HKR, Thomas SHL, Eddleston M, Sandilands EA, Coyle J, Copoper JG, Rodriguez, A, Butcher I, Lewis SC, Vliegenthart ADB, Webb DJ, Gray A. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: randomized controlled trial. *Lancet* 2014;383:697-704 [Comment p. 674].
12. Antoine DJ, Sabbisetti VS, Craig D, Simpson K, Bonventre JV, Park BK, Dear JW. Circulating kidney injury molecule-1 predicts prognosis and poor outcome in patients with

acetaminophen- induced liver injury. *Hepatology* 2015;62:591-9.

13. Shah ASV, Anand A, Sandoval Y, KK, Smith SW, Adamson PD, Chapman A, Langdon T, Sandeman D, Vaswani A, Strachan FE, Ferry A, Stirzaker A, Reid A, Gray AJ, Collinson PO, McAllister DA, Apple FS, Newby DE, Mills NL. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome. *Lancet* 2015;386:2481-8.

14. Maxwell S, Cameron IT, Webb DJ. Prescribing Safety Assessment. *Lancet* 2015;385:579–81.

15. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ for the British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. *Lancet* 2015;386:2059-68.

16. The Scottish Computed Tomography of the HEART (SCOT-HEART) Trial Investigators; Chief Investigator, Newby DE. Computed tomography coronary angiography in patients with suspected angina due to coronary heart disease. *Lancet* 2015;385:2383-91

17. Shah ASV, Anand A, Sandoval Y, Smith SW, Adamson PD, Chapman A, Langdon T, Sandeman D, Vaswani A, Strachan FE, Ferry A, Stirzaker A, Reid A, Gray AJ, Collinson PO, McAllister DA, Apple FS, Newby DE, Mills NL on behalf of the High STEACS Investigators. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome. *Lancet* 2015;386:2481-2488.

18. Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ. Endothelin. *Pharmacol Rev* 2016;68:366-427.

19. Eddleston M, Cohen A, Webb DJ. Implications of the BIA-102474-101 study for review of First- into-Human clinical trials. *Brit J Clin Pharmacol* 2016, in press.